Lv11
50 积分 2023-08-31 加入
Modification of the Classification of the Eye Changes of Graves' Disease
5天前
已完结
Teprotumumab-Associated Deafness: A Pharmacovigilance Analysis
7天前
已关闭
Systemic Adverse Events Associated with Teprotumumab Use: A Population-Based Pharmacovigilance Study
7天前
已完结
Safety profile of teprotumumab-trbw, the first and only FDA-approved treatment for thyroid-associated ophthalmopathy
7天前
已完结
Hearing abnormalities in patients treated with teprotumumab
7天前
已完结
Safety of long-term antithyroid drug treatment? A systematic review
9天前
已完结
Thyroid eye disease (Graves' orbitopathy): clinical presentation, epidemiology, pathogenesis, and management
12天前
已完结
Graves’ Disease
12天前
已完结
Teprotumumab for Thyroid-Associated Ophthalmopathy
15天前
已完结
IGF-1R Inhibitor IBI311 for the Treatment of Active Thyroid Eye Disease in Chinese Patients
16天前
已完结
皖公网安备34019202002308
